Abstract
Twelve white men with essential hypertension were treated for 1 month in randomized order with either placebo or low-dose furosemide (40 mg/day) and compared to 22 race-, age-, and diet-matched normal controls. Furosemide therapy significantly reduced mean arterial pressure (108.6 +/- 2.4 vs. 101.0 +/- 2.7 mm Hg, p < 0.02) in association with a significant increase in 24 hr urinary kallikrein activity (7.9 +/- 1.8 vs. 13.4 +/- 2.8 esterase units/24 hr, p < 0.02). Normal controls on no therapy excreted 19.4 +/- 2.6 esterase units/24 hr of urinary kallikrein activity, significantly greater than hypertensives on placebo (p < 0.01) but not hypertensives on furosemide (p > 0.1). A significant (p < 0.05) inverse correlation between mean arterial pressure and urinary kallikrein activity suggests a possible role for the kallikrein-kinin system in the antihypertensive mechanism of furosemide.
Citations
May 18, 1999·Pharmacology & Toxicology·J S Petersen
Nov 11, 1998·Clinical and Experimental Pharmacology & Physiology. Supplement·J D Penschow, B Bulmer
May 1, 1996·Ethnicity & Health·M T KailasamR J Parmer
Jun 18, 2011·BMC Nephrology·Sun Woo KangDaniel T O'Connor
Oct 1, 1982·Klinische Wochenschrift·A OverlackM Higuchi
Jan 1, 1987·Clinical and Experimental Hypertension. Part A, Theory and Practice·J F GerkensA J Smith
Jan 1, 1983·Clinical and Experimental Hypertension. Part A, Theory and Practice·H A Struyker-BoudierH van Essen
Sep 1, 1982·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·A R OlshanR A Stone
Jun 1, 1985·European Journal of Clinical Investigation·M I KoolenP van Brummelen
Aug 16, 2016·Frontiers in Physiology·Holly Digne-MalcolmKeith L Dorrington
Dec 29, 2000·Japanese Journal of Pharmacology·T FujitaM Majima
Sep 1, 1982·Hypertension·D T O'Connor
Sep 1, 1983·Hypertension·K ShimodaM H Maxwell
May 23, 2015·The Cochrane Database of Systematic Reviews·Vijaya M MusiniCiprian D Jauca